Search

Displaying results 5791 - 5800 of 10000 in total
  1. Drug

    Anacetrapib

    go.drugbank.com/drugs/DB06630
    Investigational

  2. Drug

    Valrocemide

    go.drugbank.com/drugs/DB06657
    Experimental

  3. Drug

    FP-1096

    go.drugbank.com/drugs/DB05310
    Experimental

    FP1096 reduced the painful symptoms of endometriosis in trial subjects with very minimal side effect.

  4. Drug

    TPI-ASM8

    go.drugbank.com/drugs/DB05572
    Investigational

    TPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.

  5. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer.

  6. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

  7. Drug

    Benzquinamide

    go.drugbank.com/drugs/DB00767
    ApprovedWithdrawn

    Benzquinamide is a discontinued antiemetic compound with antihistaminic, mild anticholinergic, and sedative properties. … The mechanism of action is not known, but presumably benzquinamide works via antagonism of muscarinic acetycholine receptors and histamine H1 receptors.

  8. Drug

    Oxolamine

    go.drugbank.com/drugs/DB13216
    Approved

    Oxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419]. … Oxolamine is also approved in Taiwan for the treatment of respiratory tract inflamation [L5422].

  9. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    As a second-generation (atypical) antipsychotic, it is significantly more efficacious in the treatment of the negative symptoms of schizophrenia compared to first-generation (typical) antipsychotics. … It offers improved tolerability as it lacks side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

  10. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.